Michelle Carr, Author at BioTuesdays

Developments

Verrica Pharma submits NDA for molluscum contagiosum drug

Verrica Pharmaceuticals (NASDAQ:VRCA) submitted an NDA to the FDA for its molluscum contagiosum drug candidate, VP-102. Molluscum contagiosum is a viral skin infection that currently has no FDA-approved therapies. VP...

September 16, 2019

Developments

INmune Bio receives USPTO allowance for DN-TNF-alpha platform

The U.S. Patent and Trademark Office (USPTO) gave INmune Bio (NASDAQ: INMB) notice of allowance for a patent, which covers the company’s INB03 program utilizing its dominant negative tumor necrosis factor–alpha (DN-TNF...

September 12, 2019

Developments

BeyondSpring presents Phase 3 NSCLC study design at world conference on lung cancer

BeyondSpring (NASDAQ: BYSI) presented a poster of the design for its Phase 3 Study 103 at the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain on Sept. 9. Study 103 is a multi-center...

September 10, 2019

Developments

FDA clears CytoDyn for Phase 2 combo study in metastatic colorectal cancer

The FDA has cleared CytoDyn’s (OTCQB:CYDY) to conduct a Phase 2 study for combination therapy of leronlimab and regorafenib in patients with metastatic colorectal cancer (mCRC). The Phase 2 study is a single arm study...

September 9, 2019

Markets

Janney starts Eloxx Pharma at buy; fair value estimate $14

Janney launched coverage of Eloxx Pharmaceuticals (NASDAQ:ELOX) with a “buy” rating and fair value estimate of $14. The stock closed at $5.97 on Sept. 5. Eloxx’s pipeline is focused on genetic diseases caused by...

September 6, 2019

Developments

Precipio and U of Penn in joint pathology diagnostics collaboration

Precipio (NASDAQ:PRPO) inked a new joint collaboration with the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania to expand cancer patient access to...

September 5, 2019

Developments

Versant Ventures launches medtech sector investment firm

Versant Ventures launched an independent new venture capital and growth equity investment firm dedicated to the medtech sector. Vensana Capital debuted with the closing of its inaugural fund, Vensana Capital I, with...

September 5, 2019

Developments

Repare Therapeutics raises $82.5-million in Series B financing

Closely-held Repare Therapeutics completed an $82.5-million Series B financing as it prepares to take its lead synthetic lethality therapy into human testing in 2020. Cowen Healthcare Investments led the financing and...

September 4, 2019

Markets

WB starts VistaGen Therapeutics at OP; fair value estimate $7

William Blair launched coverage of VistaGen Therapeutics (NASDAQ:VTGN) with an “outperform” rating and fair value estimate of $7. The stock closed at 60 cents on Aug. 27. VistaGen Therapeutics is focused on developing...

August 28, 2019

Developments

Zenabis outperforms cannabis design capacity by 46% in July

Zenabis Global’s (TSX:ZENA) cultivation output in July 2019 was 1,238 kg of dried cannabis, which represents a 46.2% outperformance relative to original design capacity and a 12.9% outperformance relative to revised...

August 28, 2019

Author - Michelle Carr

Verrica Pharma submits NDA for molluscum contagiosum drug

INmune Bio receives USPTO allowance for DN-TNF-alpha platform

BeyondSpring presents Phase 3 NSCLC study design at world conference on lung cancer

FDA clears CytoDyn for Phase 2 combo study in metastatic colorectal cancer

Janney starts Eloxx Pharma at buy; fair value estimate $14

Precipio and U of Penn in joint pathology diagnostics collaboration

Versant Ventures launches medtech sector investment firm

Repare Therapeutics raises $82.5-million in Series B financing

Zenabis outperforms cannabis design capacity by 46% in July

Follow Us

Subscribe

General

More

Subscribe